3/29/2013

Azithromycin and erythromycin significantly decreased the number of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis, but long-term use increased resistance to the drugs, according to two studies in the Journal of the American Medical Association. Azithromycin and erythromycin enhanced lung function, while azithromycin significantly improved quality of life.

Related Summaries